Events & Ideas

Our Work

Prescription Medicines

Psychedelics: Where we are now, why we got here, what we must do

Belouin S, Henningfield JE Neuropharmacology, 142:7-19, 2018. The purpose of this commentary is to provide an introduction to this special issue of Neuropharmacology with a historical perspective of psychedelic drug research, their use in psychiatric disorders, research-restricting regulatory controls, and their recent emergence as potential breakthrough therapies for several brain-related disorders. It begins with the… Read More

Dietary Ingredients & Supplements

Kratom Science Letter to the White House Office of National Drug Control Policy

Henningfield JE, Swogger MT, Walsh Z., Kruegel AC, Grundmann O, Garcia- Romeu A, Raffa RB, Griffiths RR, Brown P February 8, 2018 View PDF

OTC Products

Rx to OTC Switch (Part 1 of 2): Planning for Regulatory Success

Christine Sweeney, PhD, MPH, Director, Issues Management, Pinney Associates George Quesnelle, Senior Strategic Advisor, OTC Commercialization and Optimization, Pinney Associates Presented February 8, 2018 View Webinar Website

OTC Products

Exceeding the maximum daily dose of acetaminophen with use of different single-ingredient OTC formulations

Shiffman, S., Battista, D.R., Kelly, J.P., Malone, M.K., Weinstein, R.B., & Kaufman, D.W. (2018) Journal of the American Pharmacists Association 58(5), 499-504. PMID: 30030041 View Publication

Dietary Ingredients & Supplements

The abuse potential of kratom according to the 8 factors of the controlled substances act: implications for regulation and research

Henningfield JE, Fant RV, Wang DW Psychopharmacology (Berl). 235(2):573–589, 2018. View Publication

OTC Products

A cost effectiveness analysis of over-the-counter statins

Stomberg C, Albaugh M, Shiffman S, Sood N American Journal of Managed Care 22(5):e294-303, 2016 View Publication

OTC Products

Ten years after the Rx-to-OTC switch of nicotine replacement therapy: What have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT Health Policy, 86(1):17-26, 2008. View Publication

OTC Products

Physician involvement in recommending over-the-counter nicotine replacement therapy (research letter)

Shiffman S, Sweeney CT, Rohay JM, Ertischek MD American Journal of Preventive Medicine 32(4):358-9, 2007 View publication